ASEAN Medical Device Directive (AMDD) & CSDT Guide (2026): Complete Regional Registration, Harmonization Status & Member State Requirements

Overview of ASEAN's Medical Device Market

The Association of Southeast Asian Nations (ASEAN) represents one of the world's fastest-growing medical device markets. With a combined population of approximately 684 million people (including Timor-Leste, which joined as the 11th member in October 2025) and a combined GDP of around $3.9 trillion in 2024, ASEAN ranks as the world's fifth-largest economy.

The medical device market across ASEAN is diverse. Singapore serves as the regulatory gateway and a hub for high-value devices. Thailand, Indonesia, Malaysia, the Philippines, and Vietnam each maintain their own regulatory authorities but are progressively aligning with a common framework. Healthcare spending is rising across the region, driven by aging populations, expanding middle classes, and government investment in healthcare infrastructure.

The framework tying these markets together is the ASEAN Medical Device Directive (AMDD), signed in September 2015 by all ten member states. The AMDD aims to harmonize classification, technical documentation, and registration processes across the region through a shared tool: the Common Submission Dossier Template (CSDT).

What Is the AMDD?

The ASEAN Medical Device Directive (AMDD) is a regional agreement that establishes common principles for medical device regulation across ASEAN member states. It was signed in September 2015 and sets out:

• Essential Principles of Safety and Performance (Annexes 1 and 2) that all medical devices must meet
• Risk-based classification (A through D) using harmonized rules
• Common Submission Dossier Template (CSDT) (Annex 4) as the standard format for registration applications
• Post-Market Alerts System (PMAS) requirements (Annex 5)
• Declaration of Conformity (DoC) elements (Annex 6)

Key AMDD Articles

Article	Subject
Article 1	General provisions — only devices conforming to the AMDD may be placed on the market
Article 4	Essential principles of safety and performance
Article 5	Classification rules (risk-based, Classes A–D)
Article 6	Registration and placement on the market
Article 7	Conformity assessment procedures
Article 8	Technical documents including CSDT, PMAS, and DoC

Important Limitation

The AMDD harmonizes the structure and format of submissions — it does not create a single unified approval process. Each member state retains its own regulatory authority, review timelines, fees, labeling requirements, language obligations, and authorized representative rules. A device approved in Singapore is not automatically approved in Thailand; you must register separately in each country.

The value of the AMDD lies in reducing redundant documentation work. Once you have a CSDT prepared, you can adapt it for each ASEAN market with country-specific addenda rather than starting from scratch.

ASEAN Medical Device Classification

The AMDD adopts the Global Harmonization Task Force (GHTF) risk-based classification system. Medical devices are classified into four classes:

Class	Risk Level	Examples
Class A	Low risk	Non-invasive wound dressings, tongue depressors, manual surgical instruments
Class B	Low to moderate risk	Hypodermic needles, suction equipment, contact lenses, powered wheelchairs
Class C	Moderate to high risk	Orthopedic implants, lung ventilators, blood glucose meters, bone cement
Class D	High risk	Implantable defibrillators, heart valves, surgical meshes, neurostimulators

Classification Rules

Classification is determined by the intended purpose of the device and rules based on:

• Duration of contact: Transient (< 60 minutes), short-term (< 30 days), long-term (> 30 days)
• Invasiveness: Non-invasive, body orifice, surgically invasive
• Anatomical location: Surface of body, body orifice, tissue, central nervous system, central cardiovascular system
• Whether the device is active (depends on a source of energy other than the human body)
• Special rules: Devices incorporating medicinal substances, human/animal tissues, nanotechnology

IVDs follow separate classification rules in AMDD Annex 3, also on an A–D scale.

What Is the CSDT?

The Common Submission Dossier Template (CSDT) is the standardized format for medical device registration applications across ASEAN. It is the ASEAN counterpart of the IMDRF Summary Technical Documentation (STED) and the IMDRF Non-IVD Market Authorization Table of Contents (nIVD MA ToC).

Singapore's HSA now accepts both the ASEAN CSDT and the IMDRF ToC formats for registration submissions (GN-17 Revision 4, October 2025). This gives manufacturers flexibility to use the format that best suits their multi-market strategy.

CSDT Structure and Required Sections

The CSDT contains the following chapters:

1. Executive Summary

An overview of the device, including:

• Introductory description and intended uses/indications
• Novel features (e.g., nanotechnology)
• Commercial marketing history (list of countries where the device is sold)
• Regulatory approvals or marketing clearances obtained
• Status of any pending market clearance requests
• Important safety and performance information

2. Relevant Essential Principles and Method of Conformity

A table mapping each applicable essential principle to the evidence demonstrating conformity. This is a structured checklist showing:

• Which essential principles apply (and which do not, with justification)
• The method used to demonstrate conformity (e.g., compliance with a specific standard)
• Reference to the evidence document

3. Device Description

Detailed information about the device:

• Physical description, dimensions, materials
• Principle of operation
• Model/variant information
• Intended use and indications
• Patient population
• User profile (healthcare professional vs. layperson)
• Accessories and compatible devices

4. Design Verification and Validation

Technical evidence supporting the device's safety and performance:

• Design verification test results
• Design validation (clinical evidence or performance evaluation)
• Bench testing and simulation results
• Software verification and validation (for devices containing software)
• Animal studies (if applicable)

5. Clinical Evidence

Clinical data supporting the device's safety and performance:

• Clinical evaluation reports
• Clinical investigation data
• Literature review and systematic review findings
• Post-market clinical follow-up data
• Equivalence analysis (if claiming substantial equivalence to a predicate)

6. Device Labeling

All labeling documents:

• Instructions for Use (IFU)
• Patient information leaflets
• Labels on packaging
• Quick reference guides
• Electronic instructions (if applicable)

7. Risk Analysis

Risk management documentation:

• Risk management file per ISO 14971
• Hazard identification and risk estimation
• Risk control measures
• Residual risk evaluation
• Benefit-risk analysis

8. Manufacturer Information

Information about the manufacturer and manufacturing sites:

• Company name and address
• Manufacturing site details
• Quality management system certificates (ISO 13485)
• Manufacturing process overview

How the CSDT Differs from 510(k) and CE Technical File

Aspect	ASEAN CSDT	FDA 510(k)	EU Technical File
Format	Prescribed template with fixed sections	Free-form, predicate comparison	Based on MDR Annexes II/III
Clinical Evidence	Clinical evaluation report required	Substantial equivalence to predicate	Clinical evaluation per MDR Article 61
Risk Classification	Class A–D (AMDD rules)	Class I–III (FDA rules)	Class I–III (MDR rules)
QMS	ISO 13485 certificate	21 CFR 820 (QMSR from 2026)	ISO 13485 + NB audit
Language	English (with country-specific translations)	English	EU official language(s)

Member State Implementation Status (2026)

While all ASEAN members signed the AMDD in 2015, implementation maturity varies significantly:

Country	Authority	AMDD Status	CSDT Accepted	Key Notes
Singapore	HSA	Fully implemented	Yes (CSDT + IMDRF ToC)	Most mature framework; SHARE portal
Malaysia	MDA	Fully implemented	Yes	Joined MDSAP (Sep 2025); Singapore reliance pilot
Thailand	Thai FDA	Fully implemented	Yes (Class 2–4)	Auto-approval for Class 1 (Jan 2025); CSDT fulfillment for license transfers
Indonesia	BPOM / MoH	Fully implemented	Yes	Indonesia-specific review regardless of CE/FDA status
Philippines	FDA / CDRRHR	Transitioning	Yes (CSDT preferred)	Full AMDD implementation under Circular 2021-002; IVD regulation draft in progress
Vietnam	MOH	Partially implemented	Yes	Class A/B registration in ~7 days; broad reference agency recognition
Brunei	MOH	Early implementation	Yes	Limited medical device market
Cambodia	DDF/MoH	Early implementation	Yes	Small market, developing infrastructure
Laos	MOH	Early implementation	Partially	Limited regulatory infrastructure
Myanmar	FDA	Minimal implementation	Partially	Ongoing political instability

AMDC Work Plan 2026–2030

The ASEAN Medical Device Committee (AMDC), responsible for harmonizing regulations across member states, has adopted a 5-year work plan for 2026–2030. The plan focuses on:

1. Advancing harmonization of standards, technical regulations, and conformity assessment procedures
2. Strengthening mutual recognition of conformity assessment results in ASEAN
3. Strengthening joint ASEAN approaches for international representation
4. The work plan is scheduled for finalization by the first half of 2026

Singapore–Malaysia Regulatory Reliance Pilot

One of the most significant regional developments is the Singapore–Malaysia bilateral regulatory reliance pilot, which began on September 1, 2025, and was permanently confirmed on March 1, 2026.

How It Works

Direction	Mechanism	Timeline Benefit
Singapore → Malaysia	Devices on SMDR can use MDA's Verification Route (abridged CAB review)	~30 working days (vs. 60 days for full conformity assessment)
Malaysia → Singapore	Devices with MDA certificate get faster HSA review	Up to 30% reduction in review time

Key Requirements

• The device must be already registered on the Singapore Medical Device Register (SMDR) or hold a valid MDA certificate
• Class B, C, and D medical devices qualify
• The manufacturer must have an authorized representative in the target country
• A valid ISO 13485 certificate is required

This pilot is considered a model for broader ASEAN regulatory reliance and could expand to other member states in the future.

Malaysia's 2026 Updates

Malaysia continues to be one of the most progressive ASEAN regulators:

• Import permits: Mandatory ePermit system for all registered medical devices (enforcement postponed to July 2027)
• Class A fee revision (effective January 1, 2026): Application fee RM 500, registration fee RM 750
• Malaysia–China regulatory reliance pilot for IVDs (first phase: July–September 2025), referencing NMPA approvals
• Aesthetic devices designated as medical devices under the Medical Device (Designated Medical Devices) Order 2026 (effective June 2026)
• Malaysia joined MDSAP (September 2025), allowing manufacturers to leverage MDSAP certificates for MDA submissions

Preparing a CSDT: Step-by-Step

Step 1: Classify Your Device

Determine the AMDD risk class (A–D) using the classification rules. Check each target country's classification list, as some countries maintain supplemental lists.

Step 2: Prepare the Executive Summary

Write a concise overview covering the device description, intended use, marketing history, regulatory approvals, and key safety information. Include a synopsis of the full CSDT content.

Step 3: Map Essential Principles

Create the essential principles table. Map each applicable principle to the evidence of conformity. For principles that do not apply, provide a written justification.

Step 4: Compile Device Description

Document all physical, functional, and performance characteristics. Include model numbers, materials, accessories, and the principle of operation.

Step 5: Assemble Verification and Validation Evidence

Compile all design verification and validation test reports. For software devices, include software lifecycle documentation per IEC 62304. For electrical devices, include IEC 60601-series test reports.

Step 6: Prepare Clinical Evidence

Write or compile the clinical evaluation report. For Class B and above, clinical evidence is typically required. Options include:

• Clinical investigation data
• Systematic literature review
• Equivalence analysis to a predicate device
• Post-market clinical follow-up data

Step 7: Prepare Labeling

Draft the Instructions for Use (IFU), labels, and patient information. Note that each country will require translations into the local language (e.g., Bahasa for Malaysia and Indonesia, Thai for Thailand, Vietnamese for Vietnam).

Step 8: Complete Risk Analysis

Prepare or update the risk management file per ISO 14971. Include a country-specific risk addendum if local requirements differ.

Step 9: Add Manufacturer Information

Include ISO 13485 certificate, manufacturing site details, and a manufacturing process overview. For foreign manufacturers, your authorized representative in each country will handle the submission.

Step 10: Country-Specific Addenda

For each target market, add:

• Local authorized representative documentation
• Country-specific labeling translations
• Any additional forms required by the local authority
• Local fees and application forms

Common Pitfalls and How to Avoid Them

Pitfall	Impact	Solution
Inconsistent device descriptions across CSDT sections	Regulator queries and delays	Use identical terminology, model numbers, and descriptions throughout
Missing or expired authorized representative license	Application rejection	Verify representative's licenses (e.g., IDAK/IPAK in Indonesia, CDAKB certificate) before submission
Insufficient clinical evidence for Class C/D devices	Request for additional data, extended timeline	Prepare a robust clinical evaluation report; consider using RWE where accepted
Labeling not translated into local language	Application returned	Engage local translators early; include translations in the submission package
ISO 13485 certificate not covering all manufacturing sites	Non-conformity finding	Ensure the certificate scope covers all sites involved in the device's manufacture
Not checking country-specific classification lists	Wrong risk class selected	Cross-reference against each country's published classification guidance

Fees and Timelines by Country

Country	Typical Government Fees	Registration Timeline	Validity
Singapore	SGD 100–SDG 1,000+ by route and class	60–270 working days (Full, Abridged, Expedited routes)	5 years (renewable)
Malaysia	RM 500–RM 1,000+ by class (2026 rates)	60–120 working days	5 years (renewable)
Thailand	THB 1,000–THB 50,000 by class	30–180 working days (auto-approval for Class 1)	Indefinite (but facility license renewed every 3 years)
Indonesia	IDR 500,000–IDR 5,000,000 by class	30–90 working days	5 years (renewable)
Philippines	PHP 5,000–PHP 50,000 by class	60–180 working days	5 years (renewable)
Vietnam	VND 1,000,000–VND 20,000,000 by class	7 working days (Class A/B) to 6 months (Class C/D)	5 years (renewable)

ASEAN Regulatory Trends in 2026

Several important trends are shaping the regulatory landscape:

1. Regulatory Reliance and Mutual Recognition

The Singapore–Malaysia pilot is the most advanced example, but the trend is broader. The AMDC Work Plan 2026–2030 explicitly aims to strengthen mutual recognition of conformity assessment results. Manufacturers should expect more bilateral and multilateral reliance pathways in the coming years.

2. Digital Health and Software Regulation

Multiple ASEAN countries are developing specific frameworks for medical device software and SaMD:

• Singapore: HSA has published guidance on Predetermined Change Control Plans (PCCPs) for SaMD
• Malaysia: Draft guidance on change management for medical devices (December 2025)
• Philippines: New medical device software regulation draft (May 2025)

3. Cybersecurity Requirements

Singapore introduced a Cybersecurity Labeling Scheme for Medical Devices and published new guidance for medical device cybersecurity (March 2025). Other ASEAN regulators are expected to follow.

4. MDSAP Expansion

Malaysia's accession to MDSAP (September 2025) creates a pathway for manufacturers with MDSAP certification to streamline their Malaysian submissions. If other ASEAN countries follow, MDSAP could become a key regional compliance tool.

5. Post-Market Surveillance Harmonization

ASEAN's Medical Device Post-Market Information Exchange initiative (February 2025) aims to improve the sharing of adverse event data and safety signals across member states. This supports the PMAS framework under AMDD Annex 5.

Practical Strategy for Multi-Country ASEAN Entry

Recommended Approach

1. Start with Singapore or Malaysia — These have the most mature regulatory systems, and approval in one can facilitate registration in the other through the reliance pilot
2. Prepare a master CSDT — Invest in a high-quality base CSDT that can be adapted for each target market
3. Engage local authorized representatives early — Each country requires a local representative; their licenses and good standing are prerequisites for application
4. Parallel submissions — Once the master CSDT is ready, file simultaneously in multiple markets (with country-specific addenda)
5. Leverage existing approvals — If you have FDA clearance, CE marking, or TGA approval, most ASEAN countries will accept or reference these as part of their review

Timeline Expectations for Multi-Market Entry

Scenario	Countries	Estimated Timeline
Sequential (most conservative)	Singapore → Malaysia → Thailand	12–18 months
Parallel CSDT filing	Singapore + Malaysia + Thailand	8–12 months
Reliance pathway	Singapore → Malaysia (verification)	4–6 months after Singapore approval

FAQ

Is AMDD legally binding in all ASEAN countries?

The AMDD is a regional agreement, but its legal force depends on each member state's domestic implementation. Most countries have incorporated AMDD principles into national law, but the pace and completeness of implementation varies.

Can I use a single CSDT for all ASEAN countries?

Yes, you can use the same CSDT as the base document, but each country requires additional local documentation (authorized representative forms, translated labeling, local application forms). Think of the CSDT as 80% of the submission, with 20% being country-specific.

Do I need ISO 13485 to register in ASEAN markets?

For foreign manufacturers, ISO 13485 certification is effectively mandatory in most ASEAN countries. Some countries (like Singapore) formally require it; others accept it as evidence of a quality management system.

What is the difference between CSDT and IMDRF ToC?

The CSDT was derived from the GHTF STED format and is the standard ASEAN template. The IMDRF ToC is a newer, more comprehensive format developed by the International Medical Device Regulators Forum. Singapore now accepts both. The IMDRF format may offer advantages if you are also pursuing registration in non-ASEAN markets that accept it.

How long does it take to register a Class C medical device across ASEAN?

Expect 6–12 months per market. With a well-prepared CSDT and parallel filings, you can potentially register in 3–4 major ASEAN markets within 12–18 months.

Can a device rejected in one ASEAN country still be registered in another?

Yes. Each country makes its own regulatory decision. However, some countries may request information about previous regulatory outcomes in other jurisdictions as part of their review.

Key Takeaways

• The AMDD provides a harmonized framework for medical device regulation across ASEAN, but each member state retains its own regulatory authority
• The CSDT significantly reduces documentation burden for multi-country filings — prepare a master CSDT and adapt it for each market
• Singapore and Malaysia are the most mature markets and the best starting points for ASEAN entry, especially with the new reliance pathway
• Regulatory reliance is expanding — the Singapore–Malaysia pilot and the AMDC 2026–2030 work plan signal more mutual recognition ahead
• Country-specific requirements (language, fees, authorized representative, local addenda) are always needed on top of the CSDT
• 2026 trends to watch: digital health regulation, cybersecurity requirements, MDSAP expansion, and post-market surveillance harmonization